UNCOVER-1 and -2: Ixekizumab PASI and sPGA Response Rates Through 5 Years of Treatment, Approved Dosing Regimen Population, mNRI illustrates PASI and sPGA response rates in UNCOVER-1 and -2 through 264 weeks of treatment for patients receiving the recommended ixekizumab dosing regimen for moderate-to-severe plaque psoriasis. For the modified NRI method, missing data were considered nonresponders if patients discontinued treatment due to lack of efficacy, inadequate response, or AEs and imputed using multiple imputation in all other cases.3

Through 5 years of treatment in UNCOVER-1 and -2, the authors concluded that

• high-efficacy responses with the ixekizumab-approved dosing regimen were maintained with long-term treatment in patients with moderate-to-severe plaque psoriasis, and
• the safety profile of ixekizumab remained consistent with previous data.3

In UNCOVER-3, patients who completed the 12-week randomized induction period were able to continue to the open-label, long-term extension and received ixekizumab Q4W from weeks 12 to 60.1

High rates of response observed at week 12 were generally maintained over the long-term extension period to week 60 (UNCOVER-3: PASI Responses by Treatment Week, ITT Population, NRI). At week 60, the percentage of patients treated with the recommended dosing of ixekizumab Q2W for the first 12 weeks, followed by Q4W thereafter, attaining or maintaining sPGA (0,1) was 75%.1 

UNCOVER-3 efficacy and safety data through 108 weeks, 156 weeks, and 204 weeks have been previously reported.4-6 UNCOVER-3: PASI 75, PASI 90, and PASI 100 Response Rates Through Week 264, Approved Dosing Regimen Population, Observed Data, MI, and mNRI presents the UNCOVER-3 PASI response rates through 264 weeks for patients receiving the approved ixekizumab dosing regimen. Missing data were imputed using multiple imputation, where the missing data were handled by estimating what the observations would have been if the patient continued with the hypothetical treatment, and the modified NRI method, where missing data were considered nonresponders if patients discontinued treatment due to AEs, lack of efficacy, or relapse and imputed using multiple imputation in all other cases.7

Through 5 years of treatment in UNCOVER-3, the authors concluded that ixekizumab demonstrated sustained efficacy and a consistent safety profile in patients receiving the approved dosing regimen.4